scispace - formally typeset
A

Alessio Bratina

Researcher at University of Trieste

Publications -  36
Citations -  1662

Alessio Bratina is an academic researcher from University of Trieste. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 21, co-authored 33 publications receiving 1545 citations.

Papers
More filters
Journal ArticleDOI

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

TL;DR: In the early phase of relapsing-remitting multiple sclerosis the cognitive deterioration relies more on the development of brain parenchymal volume atrophy than on the extent of burden of disease in the brain.
Journal ArticleDOI

Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects.

TL;DR: Investigation of the relationship between involvement of specific areas of the brain and the occurrence of depression and anxiety in patients with multiple sclerosis found that anxiety is a reactive response to the psychosocial pressure put on the patients.
Journal ArticleDOI

Risk factors of multiple sclerosis: a case-control study.

TL;DR: The data collected in this study are confirmatory and support the hypothesis that etiology of MS constitutes the effect of interplay between genetic and environmental risk factors, however, the relatively small number of cases and controls prevents firm conclusions.
Journal ArticleDOI

Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study.

TL;DR: Previous correlations of sexual dysfunction with various clinical variables are confirmed and an association between sexual dysfunction and destructive lesions in the pons, as detected by MRI, in patients with relapsing-remitting multiple sclerosis is demonstrated.
Journal ArticleDOI

I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy:

TL;DR: Over a three-year period, treatment with IFN β-1a significantly slowed the progression of whole-brain and GM atrophy, and of T1-hypointense LV accumulation, when compared with the control group.